{"id":"meningococcal-vaccine-gsk-134612","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GSK 134612 is a meningococcal vaccine candidate designed to induce humoral and cellular immune responses against Neisseria meningitidis. By presenting meningococcal antigens to the immune system, the vaccine trains B and T cells to recognize and eliminate the pathogen, reducing the risk of invasive meningococcal infection.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against meningococcal antigens, providing protection against meningococcal disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:46.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease"}]},"trialDetails":[{"nctId":"NCT00955682","phase":"PHASE3","title":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-25","conditions":"Infections, Meningococcal","enrollment":342},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT00718666","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-20","conditions":"Infections, Meningococcal","enrollment":387},{"nctId":"NCT01154088","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-27","conditions":"Infections, Meningococcal","enrollment":1170},{"nctId":"NCT00614614","phase":"PHASE3","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-13","conditions":"Infections, Meningococcal","enrollment":1558},{"nctId":"NCT01235975","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-30","conditions":"Infections, Meningococcal","enrollment":400},{"nctId":"NCT01755689","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-11","conditions":"Infections, Meningococcal","enrollment":1300},{"nctId":"NCT00356369","phase":"PHASE2","title":"Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-23","conditions":"Infections, Meningococcal","enrollment":500},{"nctId":"NCT01165242","phase":"PHASE2","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-19","conditions":"Infections, Meningococcal","enrollment":1013},{"nctId":"NCT00454909","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-23","conditions":"Infections, Meningococcal","enrollment":873},{"nctId":"NCT00465816","phase":"PHASE3","title":"Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-11","conditions":"Infections, Meningococcal","enrollment":611},{"nctId":"NCT00427908","phase":"PHASE2","title":"Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-07","conditions":"Infections, Meningococcal","enrollment":613},{"nctId":"NCT01641042","phase":"PHASE3","title":"Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-10","conditions":"Infections, Meningococcal","enrollment":86},{"nctId":"NCT00974363","phase":"PHASE3","title":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Infections, Meningococcal","enrollment":697},{"nctId":"NCT00390143","phase":"PHASE2","title":"Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Infections, Meningococcal","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Meningococcal vaccine GSK 134612","genericName":"Meningococcal vaccine GSK 134612","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against meningococcal antigens, providing protection against meningococcal disease. Used for Prevention of meningococcal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}